Fluralaner Patent Expiration
About Veterinary Fluralaner
Fluralaner is used in a drug marketed by 1 company: Intervet Inc.
Other drugs containing Fluralaner are: Exzolt cattle ca1 , Exzolt , Bravecto , Bravecto 1 month
Veterinary Fluralaner Patents
Given below is the list of patents protecting Fluralaner, along with the drug name that holds that patent and the company owning that drug.
| Drug Used In | Drug Patent Number | Drug Patent Expiry | Drug Owner |
|---|---|---|---|
 | |||
| BRAVECTO QUANTUM | US7662972 | 28 Jun, 2027 | INTERVET, INC. |
| Exzolt Cattle CA1 | US7662972 | 28 Jun, 2027 | INTERVET, INC. |
| Exzolt | US12128032 | 02 Mar, 2035 | INTERVET, INC. |
| Exzolt | US11883530 | 19 Dec, 2034 | INTERVET, INC. |
| Exzolt | US11304934 | 19 Dec, 2034 | INTERVET, INC. |
| Exzolt | US10272071 | 19 Dec, 2034 | INTERVET, INC. |
| Exzolt | US10653675 | 19 Dec, 2034 | INTERVET, INC. |
| Exzolt | US7622972 | 28 Jun, 2027 | INTERVET, INC. |
| BRAVECTO | US9173870 | 22 Dec, 2031 | INTERVET, INC. |
| BRAVECTO | US9532978 | 22 Dec, 2031 | INTERVET, INC. |
| Bravecto | US7662972 | 28 Jun, 2027 | INTERVET, INC. |
| BRAVECTO | US7662972 | 28 Jun, 2027 | INTERVET, INC. |
| Bravecto | US8492311 | 04 Mar, 2025 | INTERVET, INC. |
| Bravecto | US10045969 | 04 Mar, 2025 | INTERVET, INC. |
| Bravecto | US10596157 | 04 Mar, 2025 | INTERVET, INC. |
| Bravecto | US8022089 | 04 Mar, 2025 | INTERVET, INC. |
| BRAVECTO | US8492311 | 04 Mar, 2025 | INTERVET, INC. |
| BRAVECTO | US8022089 | 04 Mar, 2025 | INTERVET, INC. |
| BRAVECTO 1 MONTH | US9173870 | 22 Dec, 2031 | INTERVET, INC. |
| BRAVECTO 1 MONTH | US7662972 | 28 Jun, 2027 | INTERVET, INC. |
| BRAVECTO 1 MONTH | US10596157 | 04 Mar, 2025 | INTERVET, INC. |
| BRAVECTO 1 MONTH | US10045969 | 04 Mar, 2025 | INTERVET, INC. |
| BRAVECTO 1 MONTH | US8022089 | 04 Mar, 2025 | INTERVET, INC. |
| BRAVECTO 1 MONTH | US10874645 | 04 Mar, 2025 | INTERVET, INC. |
| BRAVECTO 1 MONTH | US8492311 | 04 Mar, 2025 | INTERVET, INC. |
Fluralaner's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List